These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3049950)

  • 1. Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease.
    Geller RB; Vogelsang GB; Wingard JR; Yeager AM; Burns WH; Santos GW; Saral R
    J Clin Oncol; 1988 Oct; 6(10):1558-61. PubMed ID: 3049950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB; Myers S; Devine S; Larson RA; Williams SF; Park CL; O'Toole K; Chandler C; Topper RL
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.
    Yeager AM; Vogelsang GB; Jones RJ; Farmer ER; Altomonte V; Hess AD; Santos GW
    Blood; 1992 Jun; 79(11):3031-5. PubMed ID: 1586747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
    Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia.
    Crilley P; Topolsky D; Bulova S; Bigler R; Brodsky I
    Bone Marrow Transplant; 1990 Mar; 5(3):187-91. PubMed ID: 2331539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.
    Jones RJ; Piantadosi S; Mann RB; Ambinder RF; Seifter EJ; Vriesendorp HM; Abeloff MD; Burns WH; May WS; Rowley SD
    J Clin Oncol; 1990 Mar; 8(3):527-37. PubMed ID: 2307990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.
    Geller RB; Saral R; Piantadosi S; Zahurak M; Vogelsang GB; Wingard JR; Ambinder RF; Beschorner WB; Braine HG; Burns WH
    Blood; 1989 Jun; 73(8):2209-18. PubMed ID: 2659102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
    Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
    J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New conditioning regimens for high risk marrow transplants.
    Jones RJ; Santos GW
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
    Shaw PJ; Bergin ME; Burgess MA; Dalla Pozza L; Kellie SJ; Rowell G; Stevens MM; Webster BH; Bradstock KF
    J Clin Oncol; 1994 Oct; 12(10):2138-45. PubMed ID: 7931485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of combined therapy of human leucocyte antigen haploidentical related bone marrow transplantation and Chinese medicine in treating leukaemia].
    Yu RX; Zhou YH; Lin SY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Jul; 26(7):600-3. PubMed ID: 16983912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
    Talbot DC; Powles RL; Sloane JP; Rose J; Treleaven J; Aboud H; Helenglass G; Parikh P; Smith C; Rowley M
    Bone Marrow Transplant; 1990 Jul; 6(1):17-20. PubMed ID: 2202461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.